Navigation Links
Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
Date:4/20/2011

ial of JX-594 used as a single agent, will evaluate survival in advanced HCC patients who have progressed after treatment with sorafenib," stated David H. Kirn, M.D., president and chief executive officer of Jennerex.

"While the subset of patients in this trial is small, the data are quite compelling.  In prior studies we have demonstrated JX-594's ability to induce necrotic responses as a single agent. This is the first publication showing that JX-594 may sensitize tumors to subsequent treatment with VEGFR inhibitors, such as sorafenib," stated BG Rhee, Ph.D., president, Green Cross Corporation.

The publication also highlighted a case report of a complete and durable response in a patient with metastatic renal cell carcinoma (RCC) who received JX-594 in a Phase 1 intratumoral dose-escalation trial.  The patient, who had a baseline life expectancy of less than six months, had locally bulky and widely metastatic RCC.  The patient received four intratumoral injections of JX-594 and subsequently received standard therapy with sunitinib, an approved drug for RCC of the same class as sorafenib.  CT and PET scanning showed a whole-body complete response, and the patient remains alive and disease-free over four years after treatment initiation.  

About JX-594

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction, and the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis and is well-tolerated by patients. Object
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... Research and Markets( ... "Deciphering Global Major Pharmaceutical Companies, New Outsourcing ... It has been publicly recognized that ... a series of challenges in the recent years. ... overcapacities in small molecule product manufacturing; increasingly challenging ...
(Date:7/7/2015)... 2015  PAREXEL International Corporation (NASDAQ: PRXL ) will ... 2015 on Wednesday, August 5 th , 2015 after the ... on PAREXEL,s website at www.PAREXEL.com and on the ... host a conference call and live webcast at 10:00 a.m. ... the results.  To access the webcast, visit PAREXEL,s website at ...
(Date:7/7/2015)...   Bionik Laboratories Corp. (OTCBB: BNKL), ... core focus in robotic exoskeleton technology for users ... today that it has completed an additional sale ... its common stock and warrants for aggregate gross ... placement transaction.  This equity financing is the sixth ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3PAREXEL International Announces Date Of Fourth Quarter And Fiscal Year 2015 Earnings Release And Conference Call 2Bionik Laboratories Completes US$13.1 Million Private Placement 2Bionik Laboratories Completes US$13.1 Million Private Placement 3
... August 10, 2011 Agendia, a commercial-stage ... St. Gallen International Breast Cancer Conference (2011) Expert Panel,s ... patients by the particular biological subtype of their tumor ... According to the panel, "it is no longer tenable ...
... August 10, 2011 The report " ... Current Trends & Forecasts (2010   -   2015) ... administration, and applications; and studies the major market drivers, restraints, ... in North America (U.S. and Canada), Europe, Asia, Japan, ...
Cached Medicine Technology:International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 2International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 3MarketsandMarkets: "Radiopharmaceuticals for Therapy and PET/SPECT Imaging" Market to reach $4,734 Million by 2015 2MarketsandMarkets: "Radiopharmaceuticals for Therapy and PET/SPECT Imaging" Market to reach $4,734 Million by 2015 3
(Date:7/7/2015)... ... ... Safe Catch is setting revolutionary purity limits for canned tuna as the only ... Markets, Sprouts Farmers Market and Wegmans are some of the first grocers to stock ... mercury,” said Safe Catch co-founder Sean Wittenberg. “We launched Safe Catch tuna for health ...
(Date:7/7/2015)... ... 07, 2015 , ... The Immune Deficiency Foundation (IDF) launched ... using its IDF ePHR, an electronic personal health record powered by Get Real ... track their health information, including symptoms, diagnoses, medications, infusions and other critical health ...
(Date:7/7/2015)... Manistee, Michigan (PRWEB) , ... July 07, 2015 , ... ... a fundraising golf outing at the Manistee Golf and Country Club. Best Drug Rehabilitation ... went to a good cause, helping underprivileged children. Kiwanis International, the parent of the ...
(Date:7/7/2015)... ... July 07, 2015 , ... On June ... the site of the National Baptist Convention 110th Annual Session of the National ... promoting the collaboration of churches and their congregations, medical professionals and health-related organizations, ...
(Date:7/7/2015)... ... July 07, 2015 , ... Georgia Partnership for ... communities throughout Georgia, announces the launch of the first ambulance telemedicine program in ... County, GA. The new program will not only provide more immediate patient care, ...
Breaking Medicine News(10 mins):Health News:Safe Catch Launches Tuna with Lowest Mercury Limit of Any Brand 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 3Health News:Georgia Partnership for TeleHealth prepares to Launch First Ambulance Telemedicine Solution in Georgia 2
... say in a new study that parents are unaware of ... survey of 591 children aged 12 to 17, the researchers ... habits. ,Even among those children who had clear ... the study said. Details can be found in the journal ...
... allergic to them. Now they can rejoice for a new ... on sale for a whooping ?2,500!, // ,A ... off allergic reactions to cats. These special cats were bred ... on thousands of cats before identifying the perfect breed. , ...
... 24-half marathons in 24 consecutive days will not only raise ... to his employer. ,Young ran the 18th of ... step towards the noble cause. ,"I am very ... my endeavour to raise 100,000 pounds for Cancer Research UK," ...
... of the prostate could be life threatening. September has been ... skin cancer// prostrate cancer has been found to be the ... country with one out of every three men diagnosed with ... ,Prostate health is especially important for African-American men with death ...
... skilled obstetricians has left more women with the option ... of labor//, often in situations where a natural birth ... ,Obstetric trainees are often likely to opt ... obstetricians due to inexperience. ,Some of the common ...
... of polio in India on "unscientific" policy and "inadequacy" of ... ,Polio cases have risen to 297 so far this ... Indian strains of the virus in neighbouring Nepal and Bangladesh ... Organization (WHO). ,Thekakkara Jacob John, an authority on ...
Cached Medicine News:Health News:Cancer Survivor Runs Half-marathon 2Health News:C-Section A More Common Choice Nowadays 2Health News:Polio Outbreak in India due to Vaccine Failure, Says Expert 2
50L...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
250L...
Medicine Products: